vTv Therapeutics (NASDAQ:VTVT) Posts Earnings Results, Misses Estimates By $0.08 EPS

vTv Therapeutics (NASDAQ:VTVT) announced its earnings results on Thursday. The biotechnology company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.08), Zacks reports.

vTv Therapeutics Trading Up 0.6%

VTVT stock traded up $0.22 during trading on Thursday, reaching $34.61. 139,960 shares of the stock were exchanged, compared to its average volume of 100,056. The firm’s 50 day moving average is $33.36 and its 200 day moving average is $34.80. vTv Therapeutics has a twelve month low of $14.00 and a twelve month high of $44.00. The firm has a market cap of $136.36 million, a P/E ratio of -37.21 and a beta of 0.28.

Analysts Set New Price Targets

Several equities analysts have issued reports on VTVT shares. Rodman & Renshaw started coverage on vTv Therapeutics in a research note on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price target on the stock. Wall Street Zen raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. HC Wainwright lowered their price objective on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday. Weiss Ratings upgraded shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Monday, May 18th. Finally, Zacks Research lowered shares of vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.83.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its stake in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after buying an additional 12,896 shares in the last quarter. 683 Capital Management LLC bought a new stake in shares of vTv Therapeutics during the fourth quarter worth about $731,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of vTv Therapeutics during the fourth quarter worth about $221,000. Institutional investors and hedge funds own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.